Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Metabolic medicine

Building Your Multidisciplinary Care Team

At a Glance

People with chronic visceral ASMD usually need coordinated care led by a specialist in metabolic or genetic disease, with other doctors added for lung, liver, blood, heart, bone, or child health needs. Baseline tests guide monitoring over time.

Managing Chronic Visceral ASMD is not a task for a single doctor. Because the condition affects multiple systems—from your lungs and liver to your blood and bones—you need a multidisciplinary care team [1]. This team works together to monitor disease progression, manage symptoms, and coordinate treatments [2][3].

Your Core Specialized Team

Your care should be anchored by a metabolic specialist or a medical geneticist who has experience with lysosomal storage disorders [1]. This lead physician coordinates with a network of specialists. Note: Specialists are added according to your specific clinical findings, rather than automatically for every patient.

  • Genetic Counselor: Essential for explaining inheritance, interpreting gene variants, and discussing family testing.
  • Pulmonologist (Lung Specialist): Lung involvement can exist even if you don’t feel short of breath [4]. They monitor your breathing capacity and lung tissue health [2].
  • Hepatologist or Gastroenterologist (Liver/GI Specialist): These doctors track liver size, stiffness, and function. They also monitor for complications like portal hypertension (high blood pressure in the liver’s veins) [5][6].
  • Hematologist (Blood Specialist): They focus on managing low platelet counts (thrombocytopenia) and monitoring bleeding risks [5].
  • Cardiologist (Heart Specialist): If you have significant lipid abnormalities or other risk factors, a cardiologist can help assess your individualized cardiovascular risk [2][7].

For children, the team should also include a pediatrician to track growth and development, and potentially an endocrinologist if bone health or puberty is delayed [2][8].

The Baseline Visit: Your Medical Roadmap

Your first comprehensive clinic visit creates a “snapshot” of your health. This baseline data allows your team to see exactly how the disease is affecting you today [8]. You should expect the following assessments:

1. Lung Function Tests

  • Spirometry (FVC): Measures how much air you can breathe out after a deep breath [4].
  • DLCO (Diffusing Capacity): Checks how well oxygen moves from your lungs into your blood [4][8].
  • Exercise Testing: Often a six-minute walk test to see how your lungs and heart respond to physical activity [9][10].

2. Imaging and Organ Volume

  • Abdominal MRI or Ultrasound: Used to measure the volume of your liver and spleen [7][8]. MRI is generally preferred for tracking volume over time because it is highly reproducible, whereas ultrasound is dependent on the operator’s technique. Ask your doctor which method will be used consistently.
  • Liver Elastography: A non-invasive test that measures liver stiffness. While it does not directly measure scarring (fibrosis), increased stiffness can indicate fibrosis or other liver changes [11][10].
  • DXA Scan: A specialized X-ray used to measure bone mineral density [2][8].

3. Comprehensive Blood Work

  • Complete Blood Count (CBC): To check platelet and hemoglobin levels [8].
  • Liver Profile: Standard liver enzymes (AST/ALT). Depending on your liver health, doctors may also order specific tests of the liver’s “synthetic function,” such as INR or Factor V, though these are individualized and not universal monitoring tests [5][8].
  • Lipid Panel: To measure HDL (“good” cholesterol), LDL, and triglycerides [8].
  • Biomarkers: Tests for Lyso-SM (lysosphingomyelin) which reflects the overall disease burden (it is not a test of liver synthetic function) [7][8].

By organizing these specialists and completing these baseline tests, you move from a place of uncertainty to a proactive, individualized management plan.

Common questions in this guide

Who should coordinate my chronic visceral ASMD care?
Care is often coordinated by a metabolic specialist or medical geneticist who has experience with lysosomal storage disorders. This clinician can organize input from other specialists, but the lead doctor and team should be chosen according to your findings and available expertise.
Do I need to see every type of ASMD specialist?
Not every patient needs every specialist. A pulmonologist, liver specialist, hematologist, cardiologist, genetic counselor, pediatrician, or endocrinologist may be involved when your organ findings, age, or health risks make their expertise useful.
What tests are usually included in a first chronic visceral ASMD evaluation?
Baseline evaluation may include spirometry, a test of how well oxygen moves from the lungs into the blood, and a six-minute walk test. It may also include liver and spleen imaging, liver stiffness testing, a bone-density scan, and blood tests such as a complete blood count, liver profile, lipid panel, and Lyso-SM; clotting tests are individualized.
Should I have an MRI or ultrasound to measure my liver and spleen?
MRI is generally preferred for tracking liver and spleen volume over time because measurements are more reproducible. Ultrasound may also be used, but results can depend more on the person performing the test, so using the same approach consistently is important.
What does Lyso-SM tell my ASMD care team?
Lyso-SM is a blood biomarker that reflects overall ASMD disease burden; it does not measure how well the liver is making proteins needed for clotting. Liver enzymes and, when appropriate, tests such as INR or Factor V provide other information about liver health.
How does olipudase alfa fit into chronic visceral ASMD care?
Olipudase alfa is an enzyme replacement therapy used in some people with chronic visceral ASMD. Patients can ask whether their center has experience managing this treatment and how it fits with their monitoring plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Who will serve as the lead 'coordinator' for my care—a metabolic specialist, a geneticist, or someone else?
  2. 2.Does this facility have experience managing other patients on olipudase alfa (enzyme replacement therapy)?
  3. 3.Can we schedule my baseline pulmonary function tests and abdominal MRI for the same day to minimize travel?
  4. 4.Which specific imaging modality (MRI vs ultrasound) will we use to consistently track my organ volumes over time?
  5. 5.Are there any specific coagulation or portal-hypertension tests we should add to my baseline evaluation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).

    Geberhiwot T, Wasserstein M, Wanninayake S, et al.

    Orphanet journal of rare diseases 2023; (18(1)):85 doi:10.1186/s13023-023-02686-6.

    PMID: 37069638
  2. 2

    Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD).

    Wasserstein M, Dionisi-Vici C, Giugliani R, et al.

    Molecular genetics and metabolism 2019; (126(2)):98-105 doi:10.1016/j.ymgme.2018.11.014.

    PMID: 30514648
  3. 3

    Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.

    Syed YY

    Clinical drug investigation 2023; (43(5)):369-377 doi:10.1007/s40261-023-01270-x.

    PMID: 37133675
  4. 4

    The impact of interstitial lung disease in patients with acid sphingomyelinase deficiency (ASMD) - A case series.

    Costa I Colomer J, Garcia-Moyano M, Maiz L, et al.

    Respiratory medicine case reports 2025; (55()):102202 doi:10.1016/j.rmcr.2025.102202.

    PMID: 40343149
  5. 5

    [Acid sphingomyelinase deficiency (Niemann-Pick disease type B) in adulthood: A retrospective multicentric study of 28 adult cases].

    Lidove O, Belmatoug N, Froissart R, et al.

    La Revue de medecine interne 2017; (38(5)):291-299 doi:10.1016/j.revmed.2016.10.387.

    PMID: 27884455
  6. 6

    Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency.

    Cassiman D, Libbrecht L, Meersseman W, Wilmer A

    Case reports in gastrointestinal medicine 2019; (2019()):9613457 doi:10.1155/2019/9613457.

    PMID: 31080679
  7. 7

    Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria.

    Eskes ECB, van Dussen L, Brands MMMG, et al.

    Journal of inherited metabolic disease 2025; (48(1)):e12789 doi:10.1002/jimd.12789.

    PMID: 39177062
  8. 8

    Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt.

    Youssef MAM, Shaker EH, Saleh NAM

    Molecular and cellular pediatrics 2025; (12(1)):11 doi:10.1186/s40348-025-00199-9.

    PMID: 40810828
  9. 9

    A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.

    Wasserstein M, Lachmann R, Hollak C, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(7)):1425-1436 doi:10.1016/j.gim.2022.03.021.

    PMID: 35471153
  10. 10

    Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: A single center experience in Taiwan.

    Pan YW, Tsai MC, Yang CY, et al.

    Molecular genetics and metabolism reports 2023; (34()):100957 doi:10.1016/j.ymgmr.2023.100957.

    PMID: 36873248
  11. 11

    The value of MR spectroscopy and MR elastography in assessing hepatic involvement of chronic visceral acid sphingomyelinase deficiency in adults.

    Eskes ECB, van den Berg-Faaij SAM, Wassenaar NPM, et al.

    Molecular genetics and metabolism 2025; (145(2)):109107 doi:10.1016/j.ymgme.2025.109107.

    PMID: 40267638

This page is for informational purposes only and does not constitute medical advice. Your metabolic specialist and other clinicians should tailor your care team, tests, and treatment to your individual needs.

Get notified when new evidence is published on Chronic visceral acid sphingomyelinase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.